The nation of Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (£272m) over five years because of the United States' request for sensitive information.
The decision was revealed after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesman has since clarified that the US was demanding access to biological samples for scientific study and commercial gain while was unwilling to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further dialogue to reach a agreement suitable to all parties so the nation's vital HIV programme can continue.
Wider Implications
This rejection follows a comparable situation in Kenya, where a high court blocked a related health funding agreement after concerns were raised about the security of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking government-to-government agreements to boost openness and accountability.
As per reports, 16 nations in Africa have to date agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our country would provide the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our population if a new health crisis emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending frameworks previously established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This system is intended to ensure that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further discussions with our US partners on how subsequent co-operation could be designed in a way that respects the sovereignty and dignity of each country."
Medical Community Response
A leading public health body said it understood the government's concerns, but urged that negotiations should continue considering a large portion of the country's Aids initiatives were funded by international support.
"If specific concerns exist, such as those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
The situation highlights the continuing tensions between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.